title: Targeted therapy in soft tissue sarcoma-a novel direction in therapeutics.
abstract: Inherent or acquired resistance to chemotherapy is a significant problem in the treatment of soft tissue sarcomas. Over the past decade, the discovery and characterization of aberrant signaling pathways and the identification of agents that can specifically target them has led to their introduction as novel treatment options in soft-tissue sarcomas (STS). Trials of monotherapy with targeted agents have shown results below expectations often because of activation of alternative signaling pathways. This review examines the potential for tactical combinations of these drugs to overcome this problem.
authors.affiliation: Sarcoma Research Group, Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Surgery, Prince of Wales Hospital, Randwick, NSW 2031, Australia.
authors.forename: Chun Jek
authors.initials: CJ
authors.lastname: Tan
authors.affiliation: Sarcoma Research Group, Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Surgery, Prince of Wales Hospital, Randwick, NSW 2031, Australia. j.yang@unsw.edu.au.
authors.forename: Jia-Lin
authors.initials: JL
authors.lastname: Yang
authors.affiliation: Sarcoma Research Group, Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Surgery, Prince of Wales Hospital, Randwick, NSW 2031, Australia.
authors.forename: Philip
authors.initials: P
authors.lastname: Crowe
authors.affiliation: Sarcoma Research Group, Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Medical Oncology, Prince of Wales Hospital, Randwick, NSW 2031, Australia.
authors.forename: David
authors.initials: D
authors.lastname: Goldstein
keywords: Combination therapy; resistance; sarcoma; signaling pathway; targeted therapy